Exelixis develops cabozantinib-based multi-kinase inhibitors for kidney, liver, and thyroid cancers, focusing on oncology combination therapies and pipeline...
summary: Exelixis â biopharmaceutical company focused on cancer therapies, best known for cabozantinib (Cabometyx), a multi-kinase inhibitor for kidney and liver cancer.
read_when:
Researching oncology drug development and kinase inhibitors
Studying cancer treatment commercialization
Analyzing mid-cap biotech company strategies
Exploring combination therapy approaches in oncology
2023: Revenue $2.2B, expanding into new oncology indications
2024: Pipeline expansion beyond cabozantinib
åäžæš¡åŒ
Focused oncology company centered on cabozantinib (Cabometyx), a multi-kinase inhibitor targeting MET, VEGFR2, and AXL. Revenue from Cabometyx sales across kidney cancer, liver cancer, and thyroid cancer. Pipeline includes next-generation kinase inhibitors and combination therapies with immunotherapy.
æ€åæ²³åæ
Cabozantinib's multi-kinase targeting creates broader efficacy than single-target competitors. Expanded label across three cancer types diversifies revenue. Long patent life with potential extensions through combination indications.
å ³é®æ°æ®
Founded: 1994, Alameda, California
Revenue 2023: ~$2.2B
Employees: ~800
Flagship Drug: Cabometyx (cabozantinib)
Indications: Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Cancer
æ趣äºå®
Exelixis's name comes from 'helix' (DNA) and the Greek prefix for 'evolution' â reflecting their focus on evolving cancer treatments.
Cabozantinib was originally developed for thyroid cancer but found its biggest commercial success in kidney and liver cancer â a classic example of drug repurposing.
